[The alternative to hormonal treatment of menopausal vasomotor flushes: veralipride].
The effectiveness on hot flushes and clinical tolerance of veralipride were compared to those of natural estrogens in a randomized double blind trial. Forty-three patients who had undergone spontaneous menopause at least 6 months earlier were included in the study. For 20 days, twenty-one women were given 100 mg per day veralipride and twenty-two were given 1.25 mg of the reference estrogen. Three women in the estrogen group discontinued the trial without sound reasons. The number, duration and severity of hot flushes were assessed and scored at the onset of the trial and after 7 and 20 days of treatment. Statistical analysis showed no significant difference concerning effectiveness or tolerance. However, veralipride seemed to provide better control of severe hot flushes.
D000328:Adult; D002979:Climacteric / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D013469:Sulpiride / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D004967:Estrogens; D013469:Sulpiride; C027429:veralipride
L'alternative au traitement hormonal des bouffées vasomotrices de la ménopause: le véralipride.